Targeted Therapy

AMT-253, a MUC18-targeted antibody-drug conjugate, has shown encouraging results in two phase 1 melanoma studies. Among 56 evaluable melanoma patients, the overall response rate was 28.6%, with 15 confirmed partial responses, and the disease control rate reached 73.2%. Responses varied by melanoma subtype, with acral and unknown primary melanoma showing particularly strong disease control. Patients […]

Scientists have developed a new way to produce, isolate, and ship astatine-211 (At-211), a rare and unstable radioactive isotope with strong potential for targeted cancer therapy. Known as a “Goldilocks isotope,” At-211 is considered ideal for cancer treatment because it delivers powerful, localized bursts of energy that can kill cancer cells without harming nearby healthy

The FDA has approved vorasidenib, the first targeted drug for people with Grade 2 diffuse glioma that carries an IDH1 or IDH2 mutation. This marks an important advance for a slow-growing but incurable brain cancer. About 3,500 Americans are diagnosed with this type of tumor each year. Most cases (70–80%) have an IDH1 mutation. Patients

A Researchers have uncovered how lung cancer rapidly develops resistance to osimertinib, a key drug for EGFR-mutant tumors. Resistance can emerge within six to eight weeks of starting treatment, earlier than previously thought. The study identified a protein, METTL7A, as a critical driver of this process. METTL7A remodels chromatin, making it easier for cancer cells

Brain cancer continues to be a major global health burden. Patients often experience persistent headaches, seizures, memory loss, and difficulty thinking, which significantly affect quality of life. Glioblastoma (GBM) is the most common and deadliest type of brain tumor. It grows rapidly, infiltrates normal brain tissue, and is very difficult to treat. Standard care includes surgery

There have been major advances in targeted therapies for blood cancers, especially chronic lymphocytic leukemia (CLL), large B-cell lymphoma (LBCL), and myelofibrosis (MF). In CLL, treatment has largely shifted from chemotherapy to BTK inhibitors. Newer drugs like acalabrutinib (Calquence) and zanubrutinib (Brukinsa) provide strong, lasting responses with fewer side effects than older drugs such as

Cancer cells often rely on an inefficient energy process known as the Warburg effect, where glucose is converted to lactate even in the presence of oxygen. This excess lactate is not merely waste—it fuels an epigenetic process called lactylation. In lactylation, lactate is transformed into lactyl-CoA and attached to lysine residues on histone and non-histone

A new study from Weill Cornell Medicine reveals that the enzyme EZH2 drives chromosomal instability in triple-negative breast cancer (TNBC), promoting metastasis. Researchers found that overproduction of EZH2 silences the gene tankyrase 1, causing accumulation of CPAP and abnormal chromosome segregation during cell division. This faulty process enables cancer cells to spread aggressively to distant organs.

Antibody-drug conjugates (ADCs) are targeted cancer therapies that combine a monoclonal antibody with a potent chemotherapy drug, delivering treatment directly to cancer cells while sparing healthy tissue. Often called “smart bombs,” ADCs improve outcomes across several cancers. An ADC works in four steps: the antibody binds specifically to cancer cell proteins, the complex is internalized,

New first-line therapy has transformed treatment for BRAF V600E–mutated metastatic colorectal cancer (mCRC), an aggressive subtype with historically poor outcomes. FDA approval of the triple combination—encorafenib, cetuximab, and mFOLFOX6—marks a major breakthrough for these patients. The BREAKWATER trial demonstrated that this regimen doubled overall survival to 30.3 months compared with 15.1 months for standard therapy,